Year |
Citation |
Score |
2023 |
Dammen-Brower K, Tan E, Almaraz RT, Du J, Yarema KJ. Protocol Considerations for In Vitro Metabolic Glycoengineering of Non-Natural Glycans. Current Protocols. 3: e822. PMID 37358193 DOI: 10.1002/cpz1.822 |
0.396 |
|
2023 |
Saeui CT, Shah SR, Fernandez-Gil BI, Zhang C, Agatemor C, Dammen-Brower K, Mathew MP, Buettner M, Gowda P, Khare P, Otamendi-Lopez A, Yang S, Zhang H, Le A, Quinoñes-Hinojosa A, ... Yarema KJ, et al. Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway. Acs Chemical Biology. PMID 36626752 DOI: 10.1021/acschembio.2c00784 |
0.736 |
|
2022 |
Ludwig SD, Bernstein ZJ, Agatemor C, Dammen-Brower K, Ruffolo J, Rosas JM, Post JD, Cole RN, Yarema KJ, Spangler JB. A versatile design platform for glycoengineering therapeutic antibodies. Mabs. 14: 2095704. PMID 35815437 DOI: 10.1080/19420862.2022.2095704 |
0.621 |
|
2022 |
Du J, Liu X, Yarema KJ, Jia X. Glycoengineering human neural stem cells (hNSCs) for adhesion improvement using a novel thiol-modified N-acetylmannosamine (ManNAc) analog. Materials Science & Engineering. C, Materials For Biological Applications. 112675. PMID 35599100 DOI: 10.1016/j.msec.2022.112675 |
0.318 |
|
2021 |
Du J, Agatemor C, Saeui CT, Bhattacharya R, Jia X, Yarema KJ. Glycoengineering Human Neural and Adipose Stem Cells with Novel Thiol-Modified -Acetylmannosamine (ManNAc) Analogs. Cells. 10. PMID 33673061 DOI: 10.3390/cells10020377 |
0.713 |
|
2020 |
Stabach PR, Zimmerman K, Adame A, Kavanagh D, Saeui CT, Agatemor C, Gray S, Cao W, De La Cruz EM, Yarema KJ, Braddock DT. Improving the Pharmacodynamics and In Vivo Activity of ENPP1-Fc Through Protein and Glycosylation Engineering. Clinical and Translational Science. PMID 33064927 DOI: 10.1111/cts.12887 |
0.673 |
|
2020 |
Saeui CT, Cho KC, Dharmarha V, Nairn AV, Galizzi M, Shah SR, Gowda P, Park M, Austin M, Clarke A, Cai E, Buettner MJ, Ariss R, Moremen KW, Zhang H, ... Yarema KJ, et al. Cell Line-, Protein-, and Sialoglycosite-Specific Control of Flux-Based Sialylation in Human Breast Cells: Implications for Cancer Progression. Frontiers in Chemistry. 8: 13. PMID 32117864 DOI: 10.3389/Fchem.2020.00013 |
0.377 |
|
2019 |
Agatemor C, Buettner MJ, Ariss R, Muthiah K, Saeui CT, Yarema KJ. Exploiting metabolic glycoengineering to advance healthcare. Nature Reviews. Chemistry. 3: 605-620. PMID 31777760 DOI: 10.1038/s41570-019-0126-y |
0.686 |
|
2018 |
Saeui CT, Nairn AV, Galizzi M, Douville C, Gowda P, Park M, Dharmarha V, Shah SR, Clarke A, Austin M, Moremen KW, Yarema KJ. Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes. Plos One. 13: e0195812. PMID 29847599 DOI: 10.1371/Journal.Pone.0195812 |
0.364 |
|
2017 |
Kim H, Shin K, Park OK, Choi D, Kim HD, Baik S, Lee SH, Kwon SH, Yarema KJ, Hong J, Hyeon T, Hwang NS. General and Facile Coating of Single Cells via Mild Reduction. Journal of the American Chemical Society. PMID 29281277 DOI: 10.1021/Jacs.7B08440 |
0.324 |
|
2017 |
Yin B, Wang Q, Chung CY, Bhattacharya R, Ren X, Tang J, Yarema KJ, Betenbaugh MJ. A novel sugar analog enhances sialic acid production and biotherapeutic sialylation in CHO cells. Biotechnology and Bioengineering. PMID 28295160 DOI: 10.1002/Bit.26291 |
0.33 |
|
2017 |
Mathew M, Tan E, Labonte JW, Shah S, Saeui CT, Liu L, Bhattacharya R, Bovonratwet P, Gray JJ, Yarema K. GLYCOENGINEERING OF ESTERASE ACTIVITY THROUGH METABOLIC FLUX-BASED MODULATION OF SIALIC ACID. Chembiochem : a European Journal of Chemical Biology. PMID 28218815 DOI: 10.1002/Cbic.201600698 |
0.351 |
|
2016 |
Saeui CT, Yarema K. Abstract LB-054: Small molecule inhibitors of the hexosamine biosynthetic pathway and the cancer O-GlcNAcome Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-054 |
0.349 |
|
2015 |
Badr HA, AlSadek DM, Mathew MP, Li CZ, Djansugurova LB, Yarema KJ, Ahmed H. Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation. Data in Brief. 5: 481-488. PMID 26629491 DOI: 10.1016/j.dib.2015.09.043 |
0.345 |
|
2015 |
Badr HA, AlSadek DM, Mathew MP, Li CZ, Djansugurova LB, Yarema KJ, Ahmed H. Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation. Biomaterials. 70: 23-36. PMID 26295436 DOI: 10.1016/j.biomaterials.2015.08.020 |
0.39 |
|
2015 |
Tian Y, Almaraz RT, Choi CH, Li QK, Saeui C, Li D, Shah P, Bhattacharya R, Yarema KJ, Zhang H. Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells. Clinical Proteomics. 12: 11. PMID 25987888 DOI: 10.1186/s12014-015-9083-8 |
0.317 |
|
2013 |
Shah P, Yang S, Sun S, Aiyetan P, Yarema KJ, Zhang H. Mass spectrometric analysis of sialylated glycans with use of solid-phase labeling of sialic acids. Analytical Chemistry. 85: 3606-13. PMID 23445396 DOI: 10.1021/Ac3033867 |
0.316 |
|
2012 |
Mathew MP, Tan E, Shah S, Bhattacharya R, Adam Meledeo M, Huang J, Espinoza FA, Yarema KJ. Extracellular and intracellular esterase processing of SCFA-hexosamine analogs: implications for metabolic glycoengineering and drug delivery. Bioorganic & Medicinal Chemistry Letters. 22: 6929-33. PMID 23041156 DOI: 10.1016/j.bmcl.2012.09.017 |
0.329 |
|
2012 |
Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, Chen L, Zhang Z, Zhang H, Konstantopoulos K, Yarema KJ. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Molecular & Cellular Proteomics : McP. 11: M112.017558. PMID 22457533 DOI: 10.1074/Mcp.M112.017558 |
0.368 |
|
2012 |
Almaraz RT, Aich U, Khanna HS, Tan E, Bhattacharya R, Shah S, Yarema KJ. Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnology and Bioengineering. 109: 992-1006. PMID 22068462 DOI: 10.1002/bit.24363 |
0.4 |
|
2012 |
Almaraz RT, Mathew MP, Tan E, Yarema KJ. Metabolic oligosaccharide engineering: implications for selectin-mediated adhesion and leukocyte extravasation. Annals of Biomedical Engineering. 40: 806-15. PMID 22037949 DOI: 10.1007/s10439-011-0450-y |
0.326 |
|
2012 |
Schnaar R, Paulson JC, Macauley MS, Nycholat C, Pfrengle F, Rademacher C, Mahan A, Dionne K, Suscovich T, Alter G, Katoh T, Kiwamoto T, Brummet M, Bochner B, Tiemeyer M, ... ... Yarema K, et al. Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology Glycobiology. 22: 1518-1650. DOI: 10.1093/Glycob/Cws127 |
0.751 |
|
2011 |
Du J, Che PL, Aich U, Tan E, Kim HJ, Sampathkumar SG, Yarema KJ. Deciphering glycan linkages involved in Jurkat cell interactions with gold-coated nanofibers via sugar-displayed thiols. Bioorganic & Medicinal Chemistry Letters. 21: 4980-4. PMID 21684742 DOI: 10.1016/j.bmcl.2011.05.044 |
0.767 |
|
2011 |
Du J, Che PL, Wang ZY, Aich U, Yarema KJ. Designing a binding interface for control of cancer cell adhesion via 3D topography and metabolic oligosaccharide engineering. Biomaterials. 32: 5427-37. PMID 21549424 DOI: 10.1016/j.biomaterials.2011.04.005 |
0.343 |
|
2011 |
Meledeo MA, Paruchuri VDP, Du J, Wang Z, Yarema KJ. Mammalian Glycan Biosynthesis: Building a Template for Biological Recognition Carbohydrate Recognition: Biological Problems, Methods, and Applications. 1-32. DOI: 10.1002/9781118017586.ch1 |
0.626 |
|
2010 |
Tan E, Almaraz RT, Khanna HS, Du J, Yarema KJ. Experimental Design Considerations for In Vitro Non-Natural Glycan Display via Metabolic Oligosaccharide Engineering. Current Protocols in Chemical Biology. 2: 171-94. PMID 23839968 DOI: 10.1002/9780470559277.ch100059 |
0.391 |
|
2010 |
Aich U, Meledeo MA, Sampathkumar SG, Fu J, Jones MB, Weier CA, Chung SY, Tang BC, Yang M, Hanes J, Yarema KJ. Development of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogs. Glycoconjugate Journal. 27: 445-59. PMID 20458533 DOI: 10.1007/S10719-010-9292-3 |
0.769 |
|
2010 |
Du J, Yarema KJ. Carbohydrate engineered cells for regenerative medicine. Advanced Drug Delivery Reviews. 62: 671-82. PMID 20117158 DOI: 10.1016/j.addr.2010.01.003 |
0.351 |
|
2009 |
Wang Z, Du J, Che PL, Meledeo MA, Yarema KJ. Hexosamine analogs: from metabolic glycoengineering to drug discovery Current Opinion in Chemical Biology. 13: 565-572. PMID 19747874 DOI: 10.1016/j.cbpa.2009.08.001 |
0.695 |
|
2009 |
Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VD, Yarema KJ. Metabolic glycoengineering: sialic acid and beyond. Glycobiology. 19: 1382-401. PMID 19675091 DOI: 10.1093/glycob/cwp115 |
0.731 |
|
2009 |
Elmouelhi N, Aich U, Paruchuri VD, Meledeo MA, Campbell CT, Wang JJ, Srinivas R, Khanna HS, Yarema KJ. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. Journal of Medicinal Chemistry. 52: 2515-30. PMID 19326913 DOI: 10.1021/jm801661m |
0.678 |
|
2009 |
Atukorale PU, Choi SS, Aich U, Campbell CT, Meledeo MA, Yarema KJ. Chemical Biology of Cell Surface Oligosaccharides Protein Targeting With Small Molecules: Chemical Biology Techniques and Applications. 189-222. DOI: 10.1002/9780470495018.ch10 |
0.694 |
|
2008 |
Campbell CT, Aich U, Weier CA, Wang JJ, Choi SS, Wen MM, Maisel K, Sampathkumar SG, Yarema KJ. Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. Journal of Medicinal Chemistry. 51: 8135-47. PMID 19053749 DOI: 10.1021/jm800873k |
0.735 |
|
2008 |
Kim EJ, Shin HY, Park S, Sung D, Jon S, Sampathkumar SG, Yarema KJ, Choi SY, Kim K. Electrochemically active, anti-biofouling polymer adlayers on indium-tin-oxide electrodes. Chemical Communications (Cambridge, England). 3543-5. PMID 18654707 DOI: 10.1039/b804816a |
0.684 |
|
2008 |
Aich U, Campbell CT, Elmouelhi N, Weier CA, Sampathkumar SG, Choi SS, Yarema KJ. Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression. Acs Chemical Biology. 3: 230-40. PMID 18338853 DOI: 10.1021/cb7002708 |
0.359 |
|
2007 |
Daubeuf S, Aucher A, Sampathkumar SG, Preville X, Yarema KJ, Hudrisier D. Chemical labels metabolically installed into the glycoconjugates of the target cell surface can be used to track lymphocyte/target cell interplay via trogocytosis: comparisons with lipophilic dyes and biotin. Immunological Investigations. 36: 687-712. PMID 18161525 DOI: 10.1080/08820130701674596 |
0.75 |
|
2007 |
Campbell CT, Sampathkumar SG, Yarema KJ. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. Molecular Biosystems. 3: 187-94. PMID 17308665 DOI: 10.1039/b614939c |
0.792 |
|
2006 |
Sampathkumar SG, Jones MB, Yarema KJ. Metabolic expression of thiol-derivatized sialic acids on the cell surface and their quantitative estimation by flow cytometry. Nature Protocols. 1: 1840-51. PMID 17487167 DOI: 10.1038/nprot.2006.252 |
0.781 |
|
2006 |
Sampathkumar SG, Li AV, Yarema KJ. Synthesis of non-natural ManNAc analogs for the expression of thiols on cell-surface sialic acids. Nature Protocols. 1: 2377-85. PMID 17406481 DOI: 10.1038/nprot.2006.319 |
0.774 |
|
2006 |
Sampathkumar SG, Jones MB, Meledeo MA, Campbell CT, Choi SS, Hida K, Gomutputra P, Sheh A, Gilmartin T, Head SR, Yarema KJ. Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chemistry & Biology. 13: 1265-75. PMID 17185222 DOI: 10.1016/J.Chembiol.2006.09.016 |
0.809 |
|
2006 |
Sampathkumar SG, Li A, Yarema KJ. Sialic acid and the central nervous system: perspectives on biological functions, detection, imaging methods and manipulation. Cns & Neurological Disorders Drug Targets. 5: 425-40. PMID 16918394 |
0.719 |
|
2006 |
Sampathkumar SG, Li AV, Jones MB, Sun Z, Yarema KJ. Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology. Nature Chemical Biology. 2: 149-52. PMID 16474386 DOI: 10.1038/nchembio770 |
0.783 |
|
2006 |
Loo Y, Sampathkumar S, Atukorale PU, Yarema KJ, Leong KW. 356. Engineering of Cell Surface Sialic Acids for Polymeric Gene Delivery Molecular Therapy. 13: S135-S136. DOI: 10.1016/J.Ymthe.2006.08.414 |
0.402 |
|
2005 |
Salama I, Hinderlich S, Shlomai Z, Eisenberg I, Krause S, Yarema K, Argov Z, Lochmuller H, Reutter W, Dabby R, Sadeh M, Ben-Bassat H, Mitrani-Rosenbaum S. No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation. Biochemical and Biophysical Research Communications. 328: 221-6. PMID 15670773 DOI: 10.1016/J.Bbrc.2004.12.157 |
0.312 |
|
2005 |
Sampathkumar SG, Yarema KJ. Targeting cancer cells with dendrimers. Chemistry & Biology. 12: 5-6. PMID 15664507 DOI: 10.1016/j.chembiol.2004.12.007 |
0.719 |
|
2004 |
Kim EJ, Jones MB, Rhee JK, Sampathkumar SG, Yarema KJ. Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnology Progress. 20: 1674-82. PMID 15575698 DOI: 10.1021/Bp049841Q |
0.763 |
|
2004 |
Murrell MP, Yarema KJ, Levchenko A. The systems biology of glycosylation. Chembiochem : a European Journal of Chemical Biology. 5: 1334-47. PMID 15457533 DOI: 10.1002/Cbic.200400143 |
0.675 |
|
2004 |
Kim EJ, Sampathkumar SG, Jones MB, Rhee JK, Baskaran G, Goon S, Yarema KJ. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells. The Journal of Biological Chemistry. 279: 18342-52. PMID 14966124 DOI: 10.1074/Jbc.M400205200 |
0.803 |
|
2004 |
Jones MB, Teng H, Rhee JK, Lahar N, Baskaran G, Yarema KJ. Characterization of the cellular uptake and metabolic conversion of acetylated N-acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnology and Bioengineering. 85: 394-405. PMID 14755557 DOI: 10.1002/bit.10901 |
0.428 |
|
2003 |
Viswanathan K, Lawrence S, Hinderlich S, Yarema KJ, Lee YC, Betenbaugh MJ. Engineering sialic acid synthetic ability into insect cells: identifying metabolic bottlenecks and devising strategies to overcome them. Biochemistry. 42: 15215-25. PMID 14690432 DOI: 10.1021/Bi034994S |
0.376 |
|
2003 |
Luchansky SJ, Yarema KJ, Takahashi S, Bertozzi CR. GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism. The Journal of Biological Chemistry. 278: 8035-42. PMID 12499362 DOI: 10.1074/Jbc.M212127200 |
0.803 |
|
2002 |
Yarema KJ. New directions in carbohydrate engineering: a metabolic substrate-based approach to modify the cell surface display of sialic acids. Biotechniques. 31: 384-93. PMID 11515375 DOI: 10.2144/01312RV02 |
0.391 |
|
2001 |
Jacobs CL, Goon S, Yarema KJ, Hinderlich S, Hang HC, Chai DH, Bertozzi CR. Substrate specificity of the sialic acid biosynthetic pathway. Biochemistry. 40: 12864-74. PMID 11669623 DOI: 10.1021/Bi010862S |
0.8 |
|
2001 |
Yarema KJ, Bertozzi CR. Characterizing glycosylation pathways. Genome Biology. 2: REVIEWS0004. PMID 11387039 DOI: 10.1186/Gb-2001-2-5-Reviews0004 |
0.493 |
|
2001 |
Yarema KJ, Goon S, Bertozzi CR. Metabolic selection of glycosylation defects in human cells. Nature Biotechnology. 19: 553-8. PMID 11385460 DOI: 10.1038/89305 |
0.761 |
|
2000 |
Jacobs CL, Yarema KJ, Mahal LK, Nauman DA, Charters NW, Bertozzi CR. Metabolic labeling of glycoproteins with chemical tags through unnatural sialic acid biosynthesis. Methods in Enzymology. 327: 260-75. PMID 11044989 DOI: 10.1016/S0076-6879(00)27282-0 |
0.761 |
|
1999 |
Lemieux GA, Yarema KJ, Jacobs CL, Bertozzi CR. Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents Journal of the American Chemical Society. 121: 4278-4279. DOI: 10.1021/Ja984228M |
0.735 |
|
1998 |
Yarema KJ, Mahal LK, Bruehl RE, Rodriguez EC, Bertozzi CR. Metabolic delivery of ketone groups to sialic acid residues. Application To cell surface glycoform engineering. The Journal of Biological Chemistry. 273: 31168-79. PMID 9813021 DOI: 10.1074/Jbc.273.47.31168 |
0.747 |
|
1998 |
Yarema KJ, Bertozzi CR. Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents. Current Opinion in Chemical Biology. 2: 49-61. PMID 9667919 DOI: 10.1016/S1367-5931(98)80035-5 |
0.515 |
|
1997 |
Mahal LK, Yarema KJ, Bertozzi CR. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science (New York, N.Y.). 276: 1125-8. PMID 9173543 DOI: 10.1126/Science.276.5315.1125 |
0.727 |
|
1996 |
Rink SM, Yarema KJ, Solomon MS, Paige LA, Tadayoni-Rebek BM, Essigmann JM, Croy RG. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America. 93: 15063-8. PMID 8986764 DOI: 10.1073/Pnas.93.26.15063 |
0.533 |
|
1996 |
Moggs JG, Yarema KJ, Essigmann JM, Wood RD. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. The Journal of Biological Chemistry. 271: 7177-86. PMID 8636155 DOI: 10.1074/Jbc.271.12.7177 |
0.5 |
|
1995 |
Yarema KJ, Lippard SJ, Essigmann JM. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Research. 23: 4066-72. PMID 7479066 DOI: 10.1093/Nar/23.20.4066 |
0.464 |
|
1995 |
Yarema KJ, Essigmann JM. Evaluation of the Genetic Effects of Defined DNA Lesions Formed by DNA-Damaging Agents Methods. 7: 133-146. DOI: 10.1006/Meth.1995.1020 |
0.469 |
|
1994 |
Yarema KJ, Wilson JM, Lippard SJ, Essigmann JM. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. Journal of Molecular Biology. 236: 1034-48. PMID 8120885 DOI: 10.1016/0022-2836(94)90010-8 |
0.492 |
|
1993 |
Bradley LJ, Yarema KJ, Lippard SJ, Essigmann JM. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 32: 982-8. PMID 8422401 DOI: 10.1021/Bi00054A031 |
0.481 |
|
1992 |
Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proceedings of the National Academy of Sciences of the United States of America. 89: 10772-6. PMID 1438274 DOI: 10.1073/Pnas.89.22.10772 |
0.559 |
|
Show low-probability matches. |